GEODIS is a Supply Chain Operator ranking among the top companies in its field in Europe and the World. GEODIS, which is part of SNCF Logistics, which in turn is a business line of the SNCF Group, is the number one Transport and Logistics operator in France and ranked number four in Europe. The international reach includes a direct presence in 67 countries and a global network spanning over 120 countries. With its five Lines of Business (Supply Chain Optimization, Freight Forwarding, Contract Logistics, Distribution & Express and Road Transport), GEODIS manages its customers Supply Chain by providing end-to-end solutions enabled by our people, our infrastructure, processes and systems..
GEODIS helps pharmaceutical companies manage all parts of the logistics chain from air to sea freight forwarding, groupage, express, contract logistics, transport of truck loads, reverse logistics and optimization of the supply chain. We focus on offering our customers standard activity internal distribution. Once the product is received, we assess its state based on quality control standards and then prepare to deliver it to the end consumer. We not only manage all customer products with the highest quality standards but also make sure to provide entrant solutions for all our customers from logistics to transportation and even customs related problems.
In France, GEODIS has ten sites dedicated to health logistics, with more than 500 employees and 150,000 m² of storage and warehouse. We monitor all drugs and medicines around the clock with more than 14 pharmacists in charge of operations on every site. We deliver all types of products including medicines, vaccines, generics, and medical devices. We also deliver services for specific products such as ATUs (Temporary Authorizations for Use) and narcotics. We cover the entire logistics chain for the customer and even focus on preparing the product’s packaging before it has moved from the companies own premises.
Contact
GEODIS
Pascal Brossard, the Managing Director of Zambon France and President of Afipa (Association for the French self-medication medicines industry), reveals why he is confident that the self-medication market in France…
The president of Daiichi Sankyo France discusses the affiliate’s positioning and future strategy, the challenges for an international pharmaceutical company in France but also why the many strengths of France…
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Patrick Choay discusses his first foray into the pharmaceutical business world, talks about the highlights of his long and interesting career, his balanced partnership strategy for the Choay Group and…
Marc-Antoine Lucchini, the president-general manager of Sanofi France, talks about their unprecedented number of new molecules and innovations soon to be launched. He also explains the need to focus on the…
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international…
Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third…
Mr Truelle, the CEO of CDM Lavoisier, a company specialized in the pharmaceutical manufacturing of injectable solutions, reveals that one third of the French population could receive one of the…
Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape…
Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented…
The President of Pfizer France reveals how the biggest challenge the French pharma industry faces is to gain credit for its contribution to improve people´s quality of life; why France…
See our Cookie Privacy Policy Here
